Company news
Indaptus Therapeutics, Inc. news in 2025
Indaptus Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Indaptus Therapeutics Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
December 30, 2025
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
December 29, 2025
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
November 17, 2025
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
Indaptus Therapeutics Provides Clinical Update
September 4, 2025
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
September 2, 2025
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants
July 1, 2025
Indaptus Therapeutics Announces Reverse Stock Split
June 25, 2025
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
June 13, 2025
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
June 2, 2025
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit
May 8, 2025
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
March 25, 2025
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
March 20, 2025
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
March 18, 2025
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
March 13, 2025
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments
March 4, 2025
Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit
February 25, 2025
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
February 4, 2025
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 12, 2025
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
January 7, 2025